Yissum - Research Development Company of the Hebrew University

New Small Molecules for the Treatment of Neurological Conditions

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

methylene-cycloalkylacetate (MCA)-based compounds having neurotropic activity or NGF activity, that can be used in the treatment to
neurological conditions, such as for example brain disorders caused by insufficient trophic support
Project ID : 6-2018-4545

Description of the technology

Background

Neuro-protective drugs products of all types protect the brain and peripheral nervous system neurons from degeneration and injury by promoting neuronal survival, proliferation and differentiation. These products can be used in the treatment of neurological diseases such as Parkinson's disease, Alzheimer's disease, traumatic brain injuries, stroke ,psychiatric disorders and peripheral nerve injuries.

There is a high prevalence rates of neurodegenerative disease and the lack of specific treatment option. In addition, a large pharmaceutical pipeline exist for neurodegenerative disorders, consisting of approximately 1,500 products in active development.

The majority of pipeline products from 2010 are novel active pharmaceutical ingredients, with only a small proportion of products being either generics, or repositioned from other indications – most of which are at Phase I.

This indicates progress in terms of different molecules being developed as therapeutic agents within the neurodegenerative pipeline. With the high prevalence rates of neurodegenerative disease and the lack of specific treatment options, the opportunities are tremendous for the entry of novel neuroprotective drugs.

Our Innovation

The unique family of methylene-cycloalkylacetate-based molecules (MCAs) that modulate neuronal cell properties, and operate as acceptable pharmacophores for development of novel neurotropic (neurite outgrowth inducing) lead compounds. Our findings indicate that the alkene element, integrated within the cycloalkylacetate core, is indispensable for neurotropic activity. This discovered lead compounds may be improved towards development of a neurotropic drug.

Key Features

The desired MCA drug can be successfully constructed through the simple and straightforward sequence of synthetic transformations from commercially available starting materials.

Development Milestones

  • The MCAs lead compounds need further neuropharmacological characterizations for neuroprotection, neuroplasticity and nootropic activities.
  • POC in animal models of Alzheimer’s, Parkinson’s, Traumatic Brain and Peripheral Nerve Injuries.
  • Optimization, the lead compounds may be further improved by chemical synthesis to introduce additional pharmaceutical beneficial properties.

For additional reading

Methylene-Cycloalkylacetate (MCA) Scaffold-Based Compounds as Novel Neurotropic Agents.; Lankri D, Haham D, Lahiani A, Lazarovici P, Tsvelikhovsky D.

ACS Chem Neurosci. 2018 Apr 18;9(4):691-698. doi: 10.1021/acschemneuro.7b00473. Epub 2017 Dec 29.

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Philip Lazarovici
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Dmitry Tsvelikhovsky
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • small molecule

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.